Company Filing History:
5 out of 202 
2 out of 35 
1 out of 832,843 Years Active: 1998-2011
Title: Innovator in Amyloid Research: The Patents and Contributions of Russell E. Rydel
Introduction: Russell E. Rydel is a notable inventor based in Belmont, California, recognized for his significant contributions to the field of biotechnology, specifically in the area of amyloid research. With a total of eight patents to his name, Rydel's work focuses on addressing critical health challenges associated with amyloidogenic diseases.
Latest Patents: Among his latest innovations, Rydel holds patents for methods of inhibiting amyloid toxicity. These patents detail methods and compositions aimed at reducing the toxicity of amyloidogenic proteins, inhibiting the formation of amyloid deposits, and providing treatment for amyloid-associated diseases. The innovative approach involves administering a pharmaceutically effective amount of one or more agents that bind to integrins or their subunits, showcasing his commitment to advancing medical treatments.
Career Highlights: Rydel's career is marked by his tenure at prominent companies in the pharmaceutical and biotechnology sectors. He has worked with Elan Pharmaceuticals, Inc. and Athena Neurosciences, Inc., where he has contributed to research and development initiatives that have the potential to change the lives of individuals affected by neurodegenerative diseases. His work reflects a deep understanding of protein interactions and their implications in health.
Collaborations: Throughout his career, Rydel has collaborated with fellow researchers including Kate Dora Games and Dale Bernard Schenk. These partnerships have likely facilitated significant advancements in their shared research interests, contributing to the broader understanding of amyloid-related diseases and therapeutic strategies.
Conclusion: Russell E. Rydel's work exemplifies the impactful role of inventors in advancing medical science through innovation and collaboration. His eight patents, especially those focused on methods of inhibiting amyloid toxicity, underscore his commitment to developing effective treatments for serious health conditions. As research continues to evolve, Rydel's contributions will undoubtedly be a pivotal part of the ongoing dialogue around amyloid diseases and therapeutics.